Patents by Inventor Antonius Ter Laak
Antonius Ter Laak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230112499Abstract: The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and poType: ApplicationFiled: December 14, 2020Publication date: April 13, 2023Applicant: Bayer AktiengesellschaftInventors: Olaf PANKNIN, Frank SACHER, Nicole SCHMIDT, Gernot LANGER, Katrin NOWAK-REPPEL, Reinhard NUBBEMEYER, Sabine PILARI, Antje ROTTMANN, Hideki MIYATAKE ONDOZABAL, Holger SIEBENEICHER, Antonius TER LAAK, Hana CERNECKA
-
Publication number: 20220226279Abstract: The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R1, R2, R3, R4, R5, R6? Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.Type: ApplicationFiled: April 20, 2020Publication date: July 21, 2022Inventors: Léa Aurelie Bouché, Daniel Korr, Antonius ter Laak, Ernesto Amaury Fernandez-Montalvan, Naomi Barak, Roman Hillig, Roland Neuhaus, Matyas Gorjanacz, Vera Pütter, Stefan Niklaus Gradl, Simon Anthony Herbert, Steven James Ferrara, Craig Strathdee, Jacob Jaffe
-
Patent number: 11161825Abstract: The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamide compounds of general formula (I): in which R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 9, 2018Date of Patent: November 2, 2021Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Jörg Weiske, Carlo Stresemann, Stefan Nikolaus Gradl, Ulrike Röhn, Clara Christ, Holger Steuber, Manfred Husemann, Norbert Schmees, Kai Thede, Stephan Siegel, Antonius Ter Laak
-
Publication number: 20200199083Abstract: The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamide compounds of general formula (I): in which R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 9, 2018Publication date: June 25, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Jörg WEISKE, Carlo STRESEMANN, Stefan Nikolaus GRADL, Ulrike RÖHN, Clara CHRIST, Holger STEUBER, Manfred HUSEMANN, Norbert SCHMEES, Kai THEDE, Stephan SIEGEL, Antonius TER LAAK
-
Patent number: 10654818Abstract: The invention relates to furane derivatives of formula (I) as inhibitors of ATAD2, a process for their preparation and use thereof.Type: GrantFiled: November 30, 2016Date of Patent: May 19, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Markus Berger, Jan Hübner, Antonius Ter Laak, Matyas Gorjanacz, Amaury Ernesto Fernandez-Montalvan, Vincent Rodeschini, Didier Roche
-
Publication number: 20200123147Abstract: The present invention provides PRMT5 inhibiting compounds of general formula (I): A compound of general formula (I), in which R1, R2, R3 R4, R5, R6, R7 L1 and L2 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: June 21, 2018Publication date: April 23, 2020Inventors: Lea Aurelie BOUCHE, Duy NGUYEN, Daniel KORR, Marcus KOPPITZ, Antonius TER LAAK, Amaury Ernesto FERNANDEZ-MONTALVAN, Thi Thanh Uyen NGUYEN, Stefan PRECHTL, Andreas JANZER
-
Publication number: 20200087284Abstract: The present invention covers [4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2017Publication date: March 19, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD
-
Publication number: 20200085791Abstract: The present invention covers [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1H-1,2,3-triazol-5-yl)methanone compounds of general formula (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2017Publication date: March 19, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD
-
Publication number: 20200079758Abstract: The present invention covers [4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 15, 2017Publication date: March 12, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD
-
Publication number: 20190218196Abstract: The invention relates to furane derivatives of formula (I) as inhibitors of ATAD2, a process for their preparation and use thereof.Type: ApplicationFiled: November 30, 2016Publication date: July 18, 2019Inventors: Markus BERGER, Jan HÜBNER, Antonius TER LAAK, Matyas GORJANACZ, Amaury Ernesto FERNANDEZ-MONTALVAN, Vincent RODESCHINI, Didier ROCHE
-
Patent number: 10167293Abstract: The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 16, 2017Date of Patent: January 1, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Marcus Koppitz, Holger Siebeneicher, Holger Steuber, Antonius Ter Laak, Reinhard Nubbemeyer, Antje Rottmann, Horst Irlbacher, Benjamin Bader, Michaele Peters, Andrea Wagenfeld, Ildiko Terebesi
-
Publication number: 20180319807Abstract: The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 16, 2017Publication date: November 8, 2018Inventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD, Ildiko TEREBESI
-
Patent number: 10023539Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2, R3, R4, R5, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumor disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.Type: GrantFiled: December 8, 2015Date of Patent: July 17, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Jeffrey Stuart Mowat, Timo Stellfeld, Carlo Stresemann, Roman Hillig, Silke Köhr, Detlef Stöckigt, Jörg Weiske, Thomas Brumby, Naomi Barak, Clara Christ, Antonius Ter Laak, Volker Badock, Rosemary Helen Crampton, Ian Stefanuti
-
Publication number: 20180118722Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I), wherein R1, R3, R4, R5 and n have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.Type: ApplicationFiled: April 14, 2016Publication date: May 3, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Timo STELLFELD, Carlo STRESEMANN, Roman HILLIG, Silke KÖHR, Detlef STÖCKIGT, Jörg WEISKE, Naomi BARAK, Clara CHRIST, Antonius TER LAAK, Volker BADOCK
-
Publication number: 20180099937Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine- pyrazolines of general formula (I), wherein R1, R2, R3, R4 and R5 have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.Type: ApplicationFiled: April 14, 2016Publication date: April 12, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Timo STELLFELD, Jeffrey Stuart MOWAT, Carlo STRESEMANN, Roman HILLIG, Silke KÖHR, Detlef STÖCKIGT, Jörg WEISKE, Ingo HARTUNG, Naomi BARAK, Clara CHRIST, Antonius TER LAAK, Volker BADOCK, Rosemary Helen CRAMPTON, Ian STEFANUTI
-
Publication number: 20170342082Abstract: The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 16, 2017Publication date: November 30, 2017Inventors: Marcus KOPPITZ, Holger SIEBENEICHER, Holger STEUBER, Antonius TER LAAK, Reinhard NUBBEMEYER, Antje ROTTMANN, Horst IRLBACHER, Benjamin BADER, Michaele PETERS, Andrea WAGENFELD, Ildiko TEREBESI
-
Publication number: 20170342034Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2, R3, R4, R5, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.Type: ApplicationFiled: December 8, 2015Publication date: November 30, 2017Applicant: Bayer Pharma AktiengesellschaftInventors: Jeffrey Stuart MOWAT, Timo STELLFELD, Carlo STRESEMANN, Roman HILLIG, Silke KÖHR, Detlef STÖCKIGT, Jörg WEISKE, Thomas BRUMBY, Naomi BARACK, Clara CHRIST, Antonius TER LAAK, Volker BADOCK, Rosemary Helen CRAMPTON, Ian STEFANUTI
-
Patent number: 9708311Abstract: The present invention relates to novel benzimidazole derivatives of the general formula processes for their preparation and their use for the production of pharmaceutical compositions for the treatment of diseases and indications that are connected with the receptor EP4.Type: GrantFiled: December 3, 2013Date of Patent: July 18, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Olaf Peters, Nico Bräuer, Thorsten Blume, Antonius Ter Laak, Ludwig Zorn, Jens Nagel, Stefan Kaulfuss, Gernot Langer, Joachim Kuhnke
-
Patent number: 9655887Abstract: The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2H-indazole as novel EP2 receptor antagonists in combination with COX inhibitors. The invention furthermore provides a method for non-hormonal female-controlled on-demand contraception where a pharmaceutical composition comprising EP2 receptor antagonists in combination with COX inhibitors is taken on demand prior to expected sexual intercourse.Type: GrantFiled: May 16, 2014Date of Patent: May 23, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Bernhard Lindenthal, Nico Bräuer, Peter Serno, Andrea Rotgeri, Ulrike Fuhrmann, Bernd Buchmann, Anne Mengel, Ulrike Röhn, Antonius Ter Laak
-
Publication number: 20160214977Abstract: The present invention relates to novel benzimidazole derivatives of the general formula (I), processes for their preparation and their use for the production of pharmaceutical compositions for the treatment of diseases and indications that are connected with the receptor EP4.Type: ApplicationFiled: December 3, 2013Publication date: July 28, 2016Inventors: Olaf PETERS, Nico BRÄUER, Thorsten BLUME, Antonius TER LAAK, Ludwig ZORN, Jens NAGEL, Stefan KAULFUSS, Gernot LANGER, Joachim KUHNKE